# Situation: A 45-year-old man with bulky diffuse large B-cell lymphoma is admitted for his first cycle of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. Before his first rituximab dose, he was tested for hepatitis B surface antigen and core antibody. What is the reason for this testing?

> source: MyMerci (mymerci.kr)  
> url: https://mymerci.kr/pages/nclex_q.php?qn_id=629838  
> language: ko  
> subject: Nursing Practice III — Care of Clients with Problems in Surgery, Oxygenation, Fluid and Electrolytes, Infectious, Inflammatory and Immunologic Response, Cellular Aberrations

## 문제

Situation: A 45-year-old man with bulky diffuse large B-cell lymphoma is admitted for his first cycle of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.

Before his first rituximab dose, he was tested for hepatitis B surface antigen and core antibody. What is the reason for this testing?

## 보기

1. Hepatitis B infection makes lymphoma resistant to rituximab
2. Hepatitis B vaccine must be given before rituximab starts
3. Rituximab is made from plasma that may carry hepatitis B
4. Rituximab can reactivate a past hepatitis B infection **✔ 정답**

**정답: 4**

## 해설

Rituximab depletes B cells and can reactivate hepatitis B in people with current or past infection, sometimes causing fulminant hepatitis. Screening before the first dose identifies those who need antiviral prophylaxis and monitoring; this is especially important in the Philippines, where hepatitis B is common.

## 심화 해설

Why hepatitis B testing is required before rituximab

The reason for checking hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) before the first dose of rituximab is that rituximab can reactivate a past or current hepatitis B infection, which may progress to severe or fulminant hepatitis. Rituximab is a monoclonal antibody directed against CD20, a protein found on the surface of B lymphocytes. By depleting B cells, rituximab weakens the immune control that normally keeps hepatitis B virus in a dormant state. This loss of immune surveillance allows the virus to resume replication, producing a clinical flare that can be life-threatening.

Key point! The risk of reactivation is not limited to patients who are HBsAg-positive. Patients with resolved hepatitis B — meaning HBsAg-negative but anti-HBc-positive — also carry latent virus in hepatocytes and can reactivate once B-cell immunity is suppressed by rituximab [2][4].

| Serologic pattern | Interpretation | Reactivation risk with rituximab | Clinical implication |
| --- | --- | --- | --- |
| HBsAg (+), anti-HBc (+) | Chronic or active HBV infection | High | Start antiviral prophylaxis before or with rituximab; monitor HBV DNA and liver enzymes |
| HBsAg (−), anti-HBc (+) | Resolved/past HBV infection | Moderate to high | Consider antiviral prophylaxis; monitor HBV DNA and liver enzymes during and after therapy |
| HBsAg (−), anti-HBc (−) | No evidence of HBV exposure | Low | No HBV-specific prophylaxis needed; routine monitoring only |

The screening strategy therefore identifies two groups that require different levels of protection. Patients with current or past HBV infection need antiviral prophylaxis and close monitoring, because reactivation can occur even months after the last rituximab dose. In the population-based cohort study by Baker et al., HBV screening and antiviral prophylaxis were associated with a reduction in adverse reactivation outcomes among rituximab-treated patients, reinforcing the preventive value of testing before the first infusion . Similarly, Chen et al. found that among DLBCL patients with resolved hepatitis B receiving rituximab-containing chemotherapy, HBV reactivation and hepatitis occurred in a meaningful proportion of cases, and reactivation was linked to poorer survival outcomes [2].

Watch out! Do not confuse this screening with vaccination. Hepatitis B vaccine is not given immediately before rituximab to prevent reactivation; the purpose of pre-treatment testing is to detect existing infection and decide whether antiviral prophylaxis is needed. Rituximab itself is not manufactured from plasma that transmits hepatitis B, and hepatitis B infection does not make lymphoma resistant to rituximab.

The clinical sequence is straightforward: test first, then treat. If HBsAg or anti-HBc is positive, antiviral therapy such as entecavir or tenofovir is typically started before rituximab and continued for at least 6–12 months after the last dose, with serial monitoring of HBV DNA and liver function tests. This approach is especially relevant in regions with higher hepatitis B prevalence, where a larger proportion of patients may have unrecognized past infection [4]. Quality improvement data also show that systematic screening before rituximab initiation increases detection of at-risk patients and supports timely prophylaxis, reducing preventable reactivation events .References (research sources)

- [2]Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.Research articleChen KL, Chen J, Rao HL, Guo Y, Huang HQ, Zhang L (2015) · DOI: 10.1186/s40880-015-0015-9

- [4]HBV Serologic Testing Practices and Reactivation Outcomes Before Rituximab Initiation: A Retrospective Observational Study at an Academic Tertiary Care Centre.Research articleBarefah AS, Raslan OM, Alahwal HM, Mansory EM, Radhwi OO, Almutairi E, Alsayegh L, Alrabghi L, Almutairi BS, Alsaadi MA, Bahashwan SM. (2026) · DOI: 10.3390/jcm15155762

## 임상 시나리오

Rituximab and Hepatitis B ScreeningPrevent HBV reactivation before B-cell depletion
Check HBsAg and anti-HBc before the first rituximab dose. Rituximab depletes CD20-positive B cells and can reactivate latent hepatitis B, causing fulminant hepatitis.

If HBsAg positive or anti-HBc positive with HBsAg negative, start antiviral prophylaxis before or with rituximab and monitor HBV DNA and liver enzymes during and after therapy.

CautionReactivation risk is not limited to HBsAg-positive patients. Resolved infection with anti-HBc positive still carries moderate to high risk and requires prophylaxis consideration.

## 핵심 개념

- **Rituximab** — Anti-CD20 monoclonal antibody that depletes B cells and can trigger hepatitis B reactivation
- **HBsAg** — Hepatitis B surface antigen; positive indicates current or chronic HBV infection
- **Anti-HBc** — Hepatitis B core antibody; positive with negative HBsAg indicates resolved or past HBV infection
- **HBV reactivation** — Resumption of hepatitis B viral replication after immunosuppression, potentially causing fulminant hepatitis
- **Antiviral prophylaxis** — Preventive antiviral therapy started before or with immunosuppressive treatment in high-risk HBV patients

## 같은 주제 문제

- [Situation: A 52-year-old woman has invasive ductal carcinoma of the left breast, stage IIB…](https://mymerci.kr/pages/nclex_q.php?qn_id=629730)
- [Situation: A 52-year-old woman has invasive ductal carcinoma of the left breast, stage IIB…](https://mymerci.kr/pages/nclex_q.php?qn_id=629731)
- [Situation: A 52-year-old woman has invasive ductal carcinoma of the left breast, stage IIB…](https://mymerci.kr/pages/nclex_q.php?qn_id=629732)
- [Situation: A 52-year-old woman has invasive ductal carcinoma of the left breast, stage IIB…](https://mymerci.kr/pages/nclex_q.php?qn_id=629733)
- [Situation: A 52-year-old woman has invasive ductal carcinoma of the left breast, stage IIB…](https://mymerci.kr/pages/nclex_q.php?qn_id=629734)
- [Situation: A 66-year-old man with adenocarcinoma of the lower rectum undergoes abdominoper…](https://mymerci.kr/pages/nclex_q.php?qn_id=629735)
- [Situation: A 66-year-old man with adenocarcinoma of the lower rectum undergoes abdominoper…](https://mymerci.kr/pages/nclex_q.php?qn_id=629736)
- [Situation: A 66-year-old man with adenocarcinoma of the lower rectum undergoes abdominoper…](https://mymerci.kr/pages/nclex_q.php?qn_id=629737)

---

More free questions: [기출문제](https://mymerci.kr/)

_학습 참고용입니다. 실제 임상은 최신 지침과 소속 기관 프로토콜을 따르세요._